Glutathione (1,500 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: daily subcutaneous injections with no cycling, since continuous use is the standard pattern in the published trials. At 500 mg/mL, the 200 mg starting dose is 40 units and sits comfortably on a 30 or 50 unit insulin syringe, and the 400 mg standard dose is 80 units on a U-100 insulin syringe. The 600 mg dose works out to 1.2 mL, past the capacity of a single U-100 syringe, so it splits into two injections of 60 units each or draws into a 1 mL syringe instead. Sites rotate systematically across abdomen, thighs, and upper arms.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: 200 mg daily as the assessment phase, 40 units per injection.
• Weeks 3 to 6: 400 mg daily as the standard dose, 80 units per injection.
• Weeks 7 onward: 600 mg daily where extended or higher need applies, 120 units split across two injections.
• Onset varies by route: liposomal shows measurable change at roughly 2 weeks, GlyNAC moves multiple markers within weeks, oral takes 1 to 3 months, and subcutaneous sits between liposomal and oral in published research.
• Trial protocols ran 12 to 24 weeks with no tolerance development reported; effects build over months rather than days.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 2 to 4 weeks. At 500 mg/mL, 1 unit = 0.01 mL » 5 mg on a U-100 insulin syringe: 200 mg = 40 units, 400 mg = 80 units, 600 mg = 120 units (split into 2 injections).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture and light exposure.
• Reconstituted: refrigerate at 2 to 8 °C, protect from light, and use within 2 to 4 weeks.

• Avoid freeze thaw cycles; repeated temperature swings degrade the peptide.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Planning assumes continuous daily subcutaneous use at 400 mg per day, which is 2,800 mg per week, across a 12 to 24 week course.

Peptide Vials (Glutathione, 1,500 mg vial):

• At 400 mg daily, 12 weeks totals 33,600 mg (about 23 vials of 1,500 mg) and 24 weeks totals 67,200 mg (about 45 vials), while 12 weeks at 200 mg daily totals 16,800 mg, or about 12 vials; vial math does not apply to the oral, liposomal, or precursor routes.

Insulin Syringes (U-100):

• Per week: 7 syringes at 400 mg daily (80 units each), or 14 at 600 mg daily, where each dose splits into two injections.
• Full cycle: 84 to 168 syringes over 12 weeks, and 168 to 336 over 24 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 1,500 mg vial takes 3.0 mL, so one 10 mL bottle covers 3 vials: about 8 bottles for a 12 week course at 400 mg daily, and about 15 bottles for 24 weeks.

Alcohol Swabs:

• Per injection: 2 swabs, so 14 per week at 400 mg daily and 28 per week at 600 mg daily.
• Full cycle: 168 to 336 over 12 weeks, and 336 to 672 over 24 weeks, which is 2 to 7 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Alternative routes need no reconstitution. Oral glutathione runs 500 to 1000 mg daily with onset at 1 to 3 months (Richie 2015 RCT, n=54). Liposomal glutathione runs 500 to 1000 mg daily with onset around 2 weeks (Sinha 2018 pilot, n=12). The GlyNAC precursor route uses glycine 1.33 mmol/kg daily plus NAC 0.81 mmol/kg daily with onset in weeks (Kumar 2022 RCT, Baylor, 24 weeks). IV or IM glutathione is a clinical setting route with immediate onset, supported by pharmacokinetic data but no long term RCT.
• Route selection follows the bottleneck, and these are not either or strategies. A raw material gap in cysteine or glycine points to precursors such as GlyNAC or NAC. Impaired synthesis capacity from aging or metabolic dysfunction points to direct glutathione by subcutaneous, oral, liposomal, or IV routes. Impaired recycling from NAD+ depletion calls for NAD+ restoration regardless of which glutathione route is used.
• NAD+ recycling is the missed link. GSH returns to its active form through glutathione reductase, which requires NADPH, which depends on NAD+. Without addressing NAD+ status, glutathione supplementation often produces only temporary effects.
• Mitochondria maintain a separate pool, and that compartment matters most because reactive oxygen species generation is highest there. Common stacking partners are NAD+ for the recycling axis, SS-31 or MOTS-c where mitochondrial protection is the goal, and Thymosin Alpha-1 with KPV in immune protocols, since glutathione gates T cell proliferation while those agents expand Treg and modulate NF-kB.
• Blood levels do not reflect tissue levels. The pools that matter most, mitochondrial, liver, and brain, are the hardest to measure, so plasma GSH improvement does not prove deep tissue restoration. On the same note, the skin lightening claim is overstated: glutathione influences melanin synthesis, but the controlled trial evidence is limited, small, and short in duration, making it the most searched and least substantiated application.
• Regulatory Note: glutathione is not approved by the FDA for specific conditions and is classified as a dietary supplement; GlyNAC is a combination of two amino acid supplements with similar status. Research and education use only.

How This Works

Glutathione performs three distinct jobs: reactive oxygen species neutralization, toxin tagging, and immune cell gating. GSH donates electrons to neutralize reactive oxygen species and converts to GSSG, the spent form, and glutathione reductase then regenerates GSH using NADPH, which depends on NAD+ availability through the pentose phosphate pathway; this is not a one shot molecule but a continuously recycling system. In detoxification, glutathione-S-transferase attaches GSH to drug byproducts, reactive metabolites, and environmental toxins, marking them for liver export, which is the rate limiting step of phase 2 detoxification. In immunity, the 2017 Mak paper in Immunity genetically deleted glutathione synthesis in T cells: the cells still detected threats and expressed activation markers but could not proliferate, because the metabolic switch from resting energy production to rapid fuel burning expansion requires GSH to hold reactive oxygen species inside a precise window, where too much blocks signaling and too little blocks it as well. NK cells lacking glutathione synthesis show impaired metabolism, defective cytokine production, and an inability to control viral infection or tumor spread, and in antigen presenting cells the GSH to GSSG ratio controls IL-12 production, directing responses toward Th1 or Th2. The redox trap behind decline with age reinforces itself: oxidative stress rises, GSH is consumed faster, recycling demands NADPH, NADPH demands NAD+, and NAD+ falls with aging and inflammation.

Benefits & Side Effects

Observations from the published record.

• Richie 2015 oral RCT (n=54, 6 months): 1000 mg daily produced a 30 to 35% GSH increase in red blood cells, plasma, and lymphocytes, and 260% in buccal cells, with NK cell killing capacity more than doubling versus placebo at 3 months; onset was slow at 1 to 3 months.
• Sinha 2018 liposomal pilot (n=12, 4 weeks): 500 to 1000 mg daily produced roughly a 100% GSH increase in immune cells, NK killing up to 400% within 2 weeks, and lymphocyte proliferation up 60%; caveats are a small pilot, unblinded design, and industry funding.
• Kumar 2022 GlyNAC RCT (Baylor, 24 weeks): corrected glutathione deficiency in older adults, reduced oxidative stress, improved mitochondrial function, and decreased inflammation markers; well conducted at a major academic center, though single site and awaiting replication.
• T cell gating (Mak 2017, Immunity): genetic deletion of glutathione synthesis in T cells prevents proliferation despite intact receptor signaling, which makes glutathione a prerequisite for immune expansion rather than a generic support molecule.
• Liver toxin clearance is conjugation driven phase 2 detoxification, rate limited by GSH availability; NAC is the standard treatment for acetaminophen overdose precisely because it rapidly restores liver GSH.
• Side effects: mild GI discomfort with oral forms and nausea at higher NAC doses. Generally well tolerated, with no serious adverse events in controlled trials. What remains unanswered is that functional outcome data is thinner than biomarker data, optimal protocols are not standardized, and combined NAD+ plus glutathione trials are limited.

Lifestyle Factors

Complementary strategies for best outcomes.

• Address NAD+ status. Without adequate NAD+, glutathione recycling slows regardless of raw material availability, which makes this the most missed lever.
• Protein adequacy: cysteine and glycine are conditionally rate limiting precursors. Animal protein, whey, and collagen supply them, and aging often produces a glycine deficit specifically.
• Dietary cofactors: cruciferous vegetables, alliums such as garlic and onion, and eggs supply cysteine and methionine precursors, while selenium from Brazil nuts and seafood is a required cofactor for glutathione peroxidase.
• Lower the demand side. Chronic alcohol depletes glutathione directly, chronic inflammation raises GSH consumption, poor sleep impairs the NAD+ recycling axis, and reducing environmental toxic load through air and water filtration amplifies what supplementation can do.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Lu SC. Glutathione synthesis and redox biology (Biochim Biophys Acta, 2013).
2. Mak TW et al. Glutathione Primes T Cell Metabolism for Inflammation (Immunity, 2017).
3. Peterson JD et al. APC GSH/GSSG ratio and Th1/Th2 balance via IL-12 (PNAS, 1998).
4. Richie JP et al. Oral glutathione RCT, n=54, 6 months (Eur J Nutr, 2015).
5. Sinha R et al. Liposomal glutathione pilot, n=12 (Eur J Clin Nutr, 2018).
6. Kumar P et al. GlyNAC RCT in older adults, 24 weeks (J Gerontol A, 2023).